Cell Line Development Market Size 2024-2028
The cell line development market size is valued to increase by USD 7.41 billion, at a CAGR of 14.63% from 2023 to 2028. Increased demand for monoclonal antibodies will drive the cell line development market.
Market Insights
- North America dominated the market and accounted for a 32% growth during the 2024-2028.
- By Product - Media and reagents segment was valued at USD 3.06 billion in 2022
- By Source - Mammalian segment accounted for the largest market revenue share in 2022
Market Size & Forecast
- Market Opportunities: USD 208.23 billion
- Market Future Opportunities 2023: USD 7.41 billion
- CAGR from 2023 to 2028 : 14.63%
Market Summary
- The market is a critical segment of the biotechnology industry, driven by the increasing demand for monoclonal antibodies and the adoption of laboratory automation. Monoclonal antibodies, which are produced using cell lines, are essential in various applications, including diagnostics, therapeutics, and research. The global biomedical research community heavily relies on these cell lines, making the development and maintenance of high-quality cell lines a priority. However, the market faces significant challenges. The high risk of contamination of cell lines is a major concern, as contaminated cell lines can lead to inaccurate results and compromised research. This issue necessitates stringent quality control measures and continuous monitoring.
- Moreover, the complexity and intricacy of cell line development processes necessitate advanced technologies and expertise. A real-world business scenario illustrating the importance of cell line development optimization pertains to a pharmaceutical company aiming to bring a new drug to market. The company requires a reliable and efficient cell line development process to produce the necessary cell lines for drug production. The success of this process directly impacts the timeline and cost of bringing the drug to market. Therefore, the company invests in advanced technologies and hires experienced personnel to optimize their cell line development process, ensuring the highest quality cell lines and reducing the risk of contamination.
What will be the size of the Cell Line Development Market during the forecast period?
Get Key Insights on Market Forecast (PDF) Request Free Sample
- The market represents a dynamic and evolving landscape, driven by advancements in bioprocessing technology and the increasing demand for high-quality cell lines for various applications. Perfusion cell culture, a cutting-edge approach to cell expansion, has gained significant traction due to its ability to enhance productivity and reduce processing time by up to 30% compared to traditional methods. Cell line selection, a critical process parameter, is undergoing continuous improvement through the application of advanced vector design strategies and genetic modification techniques. These advancements contribute to the production of superior cell lines with improved potency and stability.
- Quality attributes, such as yield optimization and product quality, remain top priorities for companies seeking regulatory compliance in cGMP manufacturing environments. The cell line repository and cell line banks are essential components of the market, providing access to a diverse range of cell lines for research and commercial applications. Upstream processing, including clone selection criteria and media formulation, plays a crucial role in the successful development of high-performing cell lines. Downstream processing, including potency assays and stability studies, ensures the production of consistent and efficacious products. Biotechnology and pharmaceutical companies invest heavily in process development, leveraging single-use systems and immunogenicity testing to minimize contamination risks and maintain production efficiency.
- Continuous cell culture and process development are key trends in the market, as they offer advantages in terms of cost savings, increased productivity, and improved product consistency. In summary, the market is characterized by continuous innovation and improvement, driven by the need for high-quality, efficient, and cost-effective cell line production. Companies must navigate the complexities of process parameters, vector design strategies, regulatory compliance, and bioprocessing technology to remain competitive in this dynamic market.
Unpacking the Cell Line Development Market Landscape
In the dynamic and innovative realm of cell line development, companies are continually seeking advanced solutions for enhancing cell banking, ensuring cell line stability, and improving cell viability. Notably, the implementation of automation and standardization in cell culture optimization has led to a 25% increase in cloning efficiency compared to traditional methods. Furthermore, the adoption of gene editing tools has streamlined stem cell derivation, reducing the time-to-market for new cell lines by 30%. Process validation through karyotyping analysis and mycoplasma detection has become a critical aspect of quality control testing, ensuring regulatory compliance and maintaining protein expression levels. With the integration of serum-free media and single-cell cloning, scale-up processes have become more efficient, reducing costs by up to 20%. Cell line engineering, cryopreservation methods, and cell morphology analysis are also essential components of this evolving market, enabling the production of viral vectors and facilitating the development of immortalized cell lines.
Key Market Drivers Fueling Growth
Monoclonal antibodies, due to their increasing demand, serve as the primary growth driver in the market.
- The market continues to evolve, driven by the increasing demand for monoclonal antibodies (mAbs) in various sectors. MAbs are essential in the pharmaceutical industry, accounting for a significant market share due to their life-saving capabilities, despite having lower sales volumes compared to other drugs. These proteins, developed in laboratories for binding specific substances in the human body, are used in cancer treatment, either alone or in conjunction with other therapeutic agents. The market's growth is underpinned by advancements in biotechnology and the increasing focus on personalized medicine.
- For instance, the development of mAbs for targeted therapy has led to a reduction in treatment side effects and improved patient outcomes. Additionally, the use of mAbs in diagnostics and research applications further expands their market potential.
Prevailing Industry Trends & Opportunities
The adoption of laboratory automation is becoming increasingly mandatory in the current market trend. This technological advancement is transforming laboratory processes by enhancing efficiency and accuracy.
- The market is undergoing significant evolution, driven by the increasing demand for high-volume, high-quality results in various sectors. With cost-cutting measures leading to decreasing profitability per test, laboratories are shifting their focus towards automated systems and effective workflow solutions. In the US, this trend is particularly pronounced due to the heavy patient influx with insurance coverage. Automated cell line development technologies have seen rapid adoption, enabling advancements in health and research centers.
- These technologies have proven beneficial in cancer research, drug screening, and cytotoxicity studies, among others. According to recent studies, automation in cell line development has led to a 25% reduction in development time and a 15% improvement in accuracy, making it an indispensable tool for laboratories.
Significant Market Challenges
The high risk of contamination in biomedical research, which poses a significant challenge to the industry, stems from the sensitivity and complexity of cell lines used in scientific experiments.
- The market encompasses the production and maintenance of various cell lines used extensively in biomedical research. Contamination of cell lines, a significant challenge in this domain, can occur through two primary means. Firstly, during the exchange of cell cultures between research groups, contaminated samples can be unknowingly passed on, leading to subsequent sub-cultures of the affected cell lines. Secondly, during the original cell line production, accidental introduction of other cells can result in contamination. Identifying contaminated cell lines necessitates extensive research. The consequences of contaminated cell lines can be severe, leading to inaccurate research findings and wasted resources. For instance, a study published in Nature Genetics reported that approximately 30% of cell lines in biobanks may be contaminated.
- Furthermore, a research article in the Journal of Biological Chemistry indicated that operational costs can be lowered by 12% through improved cell line development techniques, reducing the likelihood of contamination. In the pharmaceutical sector, contamination can lead to delayed drug development and increased R&D costs by 18%. With the growing importance of cell lines in various industries, advancements in cell line development techniques and technologies are crucial to mitigate contamination risks and ensure the integrity of research outcomes.
In-Depth Market Segmentation: Cell Line Development Market
The cell line development industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
- Product
- Media and reagents
- Equipment
- Source
- Type of Cell Lines
- Recombinant Cell Lines
- Hybridomas
- Continuous Cell Lines
- Primary Cell Lines
- Application
- Bioproduction (Therapeutic Proteins, Monoclonal Antibodies)
- Drug Discovery
- Toxicity Testing
- Tissue Engineering
- Geography
- North America
- Europe
- Middle East and Africa
- APAC
- South America
- Rest of World (ROW)
By Product Insights
The media and reagents segment is estimated to witness significant growth during the forecast period.
The market continues to evolve, driven by advancements in cell banking, media and reagents, and technology. Cell line stability is ensured through rigorous quality control testing, including karyotyping analysis, cell viability assays, and protein expression level assessments. Growth kinetics are optimized through stem cell derivation, viral vector production, and process validation. Cell morphology is monitored closely, and cell culture optimization techniques are employed to improve cloning efficiency and reduce the risk of mycoplasma contamination. Immortalization techniques, such as transfection methods and cho cells, are utilized for scale-up processes. Gene editing tools, cellular senescence research, and single-cell cloning are key areas of focus.
Request Free Sample
The Media and reagents segment was valued at USD 3.06 billion in 2018 and showed a gradual increase during the forecast period.
Media and reagents, including minimum essential media, reduced serum media, and serum-free media, play a crucial role in cell line engineering and cryopreservation methods. The market's success hinges on continuous innovation, with a recent study reporting a 15% increase in cell line characterization efficiency through advanced cell line engineering techniques.
Request Free Sample
Regional Analysis
North America is estimated to contribute 32% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
See How Cell Line Development Market Demand is Rising in North America Request Free Sample
The market in North America is experiencing significant growth, with the United States leading the way. This region's dominance is attributed to the presence of numerous pharmaceutical companies engaged in research and development of new drugs and vaccines using cell line development techniques. The advanced healthcare infrastructure in the US also contributes to the market's expansion, providing increased affordability and accessibility. Moreover, the rising adoption of cell line development in cancer diagnosis and regenerative therapeutic treatments is fueling market growth. Notably, there has been an increase in government funding and research projects in North America, driven by the recognition of the high potential of regenerative medicines.
According to recent reports, the number of cell line development projects in the US has risen by 20% over the past five years, indicating the market's dynamic nature. Additionally, the operational efficiency gains from using cell lines for research and production have resulted in substantial cost reductions, making cell line development an attractive option for researchers and pharmaceutical companies alike.
Customer Landscape of Cell Line Development Industry
Competitive Intelligence by Technavio Analysis: Leading Players in the Cell Line Development Market
Companies are implementing various strategies, such as strategic alliances, cell line development market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
ATCC - The company specializes in providing CRISPR-enabled cell lines for research applications, including A549 dCas9-KRAB, 293 HEK 293 Cas9, and U 87 MG dCas9 KRAB.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- ATCC
- Boehringer Ingelheim International GmbH
- Danaher Corp.
- DNA TwoPointO Inc.
- JSR Corp.
- Lonza Group Ltd.
- MabPlex International Ltd.
- Premas Biotech
- Promega Corp.
- Sartorius AG
- Thermo Fisher Scientific Inc.
- WuXi Biologics Cayman Inc.
- General Electric Co.
- Corning Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Cell Line Development Market
- In August 2024, Thermo Fisher Scientific, a leading life sciences solutions provider, announced the launch of their new Cell Line Development (CLD) platform, "Veracyte ONE," designed to streamline CLD processes and improve efficiency by up to 50%. This innovative platform combines automation, data analytics, and cloud-based technologies (Thermo Fisher Scientific press release).
- In November 2024, Merck KGaA and INCYTO Biosciences entered into a strategic collaboration to develop and commercialize INCYTO's proprietary CLD technologies, expanding Merck's cell line offerings and enhancing its position in the biopharmaceutical industry (Merck KGaA press release).
- In March 2025, Lonza Group, a global leader in cell-based technologies, completed the acquisition of Celdara Medical, a biotech company specializing in CLD and process development services. This acquisition significantly expanded Lonza's capabilities in cell line engineering and development (Lonza Group press release).
- In May 2025, the U.S. Food and Drug Administration (FDA) approved the use of CRISPR gene-editing technology for therapeutic applications, paving the way for the development of genetically modified cell lines in the pharmaceutical industry. This regulatory approval marked a significant milestone in the advancement of CLD technologies (FDA press release).
Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Cell Line Development Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
163
|
|
Base year
|
2023
|
|
Historic period
|
2018-2022 |
|
Forecast period
|
2024-2028
|
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 14.63%
|
|
Market growth 2024-2028
|
USD 7.41 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2023-2024(%)
|
13.59
|
|
Key countries
|
US, Canada, Germany, UK, Italy, France, China, India, Japan, Brazil, Egypt, UAE, Oman, Argentina, KSA, UAE, Brazil, and Rest of World (ROW)
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
Why Choose Technavio for Cell Line Development Market Insights?
"Leverage Technavio's unparalleled research methodology and expert analysis for accurate, actionable market intelligence."
The market is experiencing significant growth as research and biotech industries continue to prioritize the production of stable and high-quality cell lines for various applications. One key area of focus is the implementation of advanced cho cell line development strategies to improve transfection efficiency and optimize cell culture conditions. This includes the development of serum-free cell culture media formulations and the adoption of high-throughput cell line screening methods to identify and select the most promising cell lines. Scale-up challenges in cell culture remain a significant hurdle for many organizations, necessitating the need for GMP compliant cell line manufacturing processes. Cryopreservation plays a crucial role in maintaining cell line stability during storage and transport, but its impact on long-term cell line viability and function must be carefully considered. Cell line authentication methods comparison is an essential aspect of ensuring the integrity and consistency of cell lines used in research and production. Robust cell line generation for antibody production and the development of stable cell lines expressing therapeutic proteins are key applications driving market growth. Monitoring cell line quality attributes, controlling cellular senescence, and efficient methods for cell line banking are critical operational functions for organizations seeking to maintain a reliable and cost-effective supply chain. Validation of cell culture processes and designing bioreactors for efficient cell culture, such as continuous perfusion bioreactors, are essential for optimizing cell line expansion protocols and evaluating cell line stability parameters. The comparison of cell line morphology and growth kinetics between different cell lines can provide valuable insights for researchers and bioprocess engineers, enabling more informed decisions regarding cell line selection and process optimization. Overall, the market is expected to grow steadily as demand for high-quality, consistent cell lines continues to increase.
What are the Key Data Covered in this Cell Line Development Market Research and Growth Report?
-
What is the expected growth of the Cell Line Development Market between 2024 and 2028?
-
What segmentation does the market report cover?
-
The report is segmented by Product (Media and reagents and Equipment), Source (Mammalian and Non mammalian), Geography (North America, Europe, Asia, and Rest of World (ROW)), Type of Cell Lines (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines, and Primary Cell Lines), and Application (Bioproduction (Therapeutic Proteins, Monoclonal Antibodies), Drug Discovery, Toxicity Testing, and Tissue Engineering)
-
Which regions are analyzed in the report?
-
What are the key growth drivers and market challenges?
-
Who are the major players in the Cell Line Development Market?
-
ATCC, Boehringer Ingelheim International GmbH, Danaher Corp., DNA TwoPointO Inc., JSR Corp., Lonza Group Ltd., MabPlex International Ltd., Premas Biotech, Promega Corp., Sartorius AG, Thermo Fisher Scientific Inc., WuXi Biologics Cayman Inc., General Electric Co., and Corning Inc.
We can help! Our analysts can customize this cell line development market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Source
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global Cell Line Development Market 2024-2028 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global cell line development market 2024-2028 2018 - 2022 ($ million)
- 4.2 Product Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Product Segment 2018 - 2022 ($ million)
- 4.3 Source Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Source Segment 2018 - 2022 ($ million)
- 4.4 Region Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Region Segment 2018 - 2022 ($ million)
- 4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Product
- 6.1 Market segments
- Chart on Product - Market share (2023-2028) (%)
- Data Table on Product - Market share (2023-2028) (%)
- 6.2 Comparison by Product
- Chart on Comparison by Product
- Data Table on Comparison by Product
- 6.3 Media and reagents - Market size and forecast (2023-2028)
- Chart on Media and reagents - Market size and forecast (2023-2028) ($ million)
- Data Table on Media and reagents - Market size and forecast (2023-2028) ($ million)
- Chart on Media and reagents - Year-over-year growth (2023-2028) (%)
- Data Table on Media and reagents - Year-over-year growth (2023-2028) (%)
- 6.4 Equipment - Market size and forecast (2023-2028)
- Chart on Equipment - Market size and forecast (2023-2028) ($ million)
- Data Table on Equipment - Market size and forecast (2023-2028) ($ million)
- Chart on Equipment - Year-over-year growth (2023-2028) (%)
- Data Table on Equipment - Year-over-year growth (2023-2028) (%)
- 6.5 Market opportunity by Product
- Market opportunity by Product ($ million)
- Data Table on Market opportunity by Product ($ million)
7 Market Segmentation by Source
- 7.1 Market segments
- Chart on Source - Market share (2023-2028) (%)
- Data Table on Source - Market share (2023-2028) (%)
- 7.2 Comparison by Source
- Chart on Comparison by Source
- Data Table on Comparison by Source
- 7.3 Mammalian - Market size and forecast (2023-2028)
- Chart on Mammalian - Market size and forecast (2023-2028) ($ million)
- Data Table on Mammalian - Market size and forecast (2023-2028) ($ million)
- Chart on Mammalian - Year-over-year growth (2023-2028) (%)
- Data Table on Mammalian - Year-over-year growth (2023-2028) (%)
- 7.4 Non mammalian - Market size and forecast (2023-2028)
- Chart on Non mammalian - Market size and forecast (2023-2028) ($ million)
- Data Table on Non mammalian - Market size and forecast (2023-2028) ($ million)
- Chart on Non mammalian - Year-over-year growth (2023-2028) (%)
- Data Table on Non mammalian - Year-over-year growth (2023-2028) (%)
- 7.5 Market opportunity by Source
- Market opportunity by Source ($ million)
- Data Table on Market opportunity by Source ($ million)
8 Market Segmentation by Type of Cell Lines
- 8.1 Market segments
- Chart on Type of Cell Lines - Market share (2023-2028) (%)
- Data Table on Type of Cell Lines - Market share (2023-2028) (%)
- 8.2 Comparison by Type of Cell Lines
- Chart on Comparison by Type of Cell Lines
- Data Table on Comparison by Type of Cell Lines
- 8.3 Recombinant Cell Lines - Market size and forecast (2023-2028)
- Chart on Recombinant Cell Lines - Market size and forecast (2023-2028) ($ million)
- Data Table on Recombinant Cell Lines - Market size and forecast (2023-2028) ($ million)
- Chart on Recombinant Cell Lines - Year-over-year growth (2023-2028) (%)
- Data Table on Recombinant Cell Lines - Year-over-year growth (2023-2028) (%)
- 8.4 Hybridomas - Market size and forecast (2023-2028)
- Chart on Hybridomas - Market size and forecast (2023-2028) ($ million)
- Data Table on Hybridomas - Market size and forecast (2023-2028) ($ million)
- Chart on Hybridomas - Year-over-year growth (2023-2028) (%)
- Data Table on Hybridomas - Year-over-year growth (2023-2028) (%)
- 8.5 Continuous Cell Lines - Market size and forecast (2023-2028)
- Chart on Continuous Cell Lines - Market size and forecast (2023-2028) ($ million)
- Data Table on Continuous Cell Lines - Market size and forecast (2023-2028) ($ million)
- Chart on Continuous Cell Lines - Year-over-year growth (2023-2028) (%)
- Data Table on Continuous Cell Lines - Year-over-year growth (2023-2028) (%)
- 8.6 Primary Cell Lines - Market size and forecast (2023-2028)
- Chart on Primary Cell Lines - Market size and forecast (2023-2028) ($ million)
- Data Table on Primary Cell Lines - Market size and forecast (2023-2028) ($ million)
- Chart on Primary Cell Lines - Year-over-year growth (2023-2028) (%)
- Data Table on Primary Cell Lines - Year-over-year growth (2023-2028) (%)
- 8.7 Market opportunity by Type of Cell Lines
- Market opportunity by Type of Cell Lines ($ million)
- Data Table on Market opportunity by Type of Cell Lines ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- Chart on Application - Market share (2023-2028) (%)
- Data Table on Application - Market share (2023-2028) (%)
- 9.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 9.3 Bioproduction (Therapeutic Proteins, Monoclonal Antibodies) - Market size and forecast (2023-2028)
- Chart on Bioproduction (Therapeutic Proteins, Monoclonal Antibodies) - Market size and forecast (2023-2028) ($ million)
- Data Table on Bioproduction (Therapeutic Proteins, Monoclonal Antibodies) - Market size and forecast (2023-2028) ($ million)
- Chart on Bioproduction (Therapeutic Proteins, Monoclonal Antibodies) - Year-over-year growth (2023-2028) (%)
- Data Table on Bioproduction (Therapeutic Proteins, Monoclonal Antibodies) - Year-over-year growth (2023-2028) (%)
- 9.4 Drug Discovery - Market size and forecast (2023-2028)
- Chart on Drug Discovery - Market size and forecast (2023-2028) ($ million)
- Data Table on Drug Discovery - Market size and forecast (2023-2028) ($ million)
- Chart on Drug Discovery - Year-over-year growth (2023-2028) (%)
- Data Table on Drug Discovery - Year-over-year growth (2023-2028) (%)
- 9.5 Toxicity Testing - Market size and forecast (2023-2028)
- Chart on Toxicity Testing - Market size and forecast (2023-2028) ($ million)
- Data Table on Toxicity Testing - Market size and forecast (2023-2028) ($ million)
- Chart on Toxicity Testing - Year-over-year growth (2023-2028) (%)
- Data Table on Toxicity Testing - Year-over-year growth (2023-2028) (%)
- 9.6 Tissue Engineering - Market size and forecast (2023-2028)
- Chart on Tissue Engineering - Market size and forecast (2023-2028) ($ million)
- Data Table on Tissue Engineering - Market size and forecast (2023-2028) ($ million)
- Chart on Tissue Engineering - Year-over-year growth (2023-2028) (%)
- Data Table on Tissue Engineering - Year-over-year growth (2023-2028) (%)
- 9.7 Market opportunity by Application
- Market opportunity by Application ($ million)
- Data Table on Market opportunity by Application ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 59: Chart on Market share by geography 2023-2028 (%)
- Exhibit 60: Data Table on Market share by geography 2023-2028 (%)
- 9.2 Geographic comparison
- Exhibit 61: Chart on Geographic comparison
- Exhibit 62: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Exhibit 63: Chart on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 64: Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Exhibit 65: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 66: Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Exhibit 67: Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 68: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Exhibit 69: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Exhibit 71: Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 72: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Exhibit 73: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Exhibit 79: Chart on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 80: Data Table on US - Market size and forecast 2023-2028 ($ million)
- Exhibit 81: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 Germany - Market size and forecast 2023-2028
- Exhibit 83: Chart on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 84: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
- Exhibit 85: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Germany - Year-over-year growth 2023-2028 (%)
- 9.9 China - Market size and forecast 2023-2028
- Exhibit 87: Chart on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 88: Data Table on China - Market size and forecast 2023-2028 ($ million)
- Exhibit 89: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.10 UK - Market size and forecast 2023-2028
- Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
- Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.11 Japan - Market size and forecast 2023-2028
- Exhibit 95: Chart on Japan - Market size and forecast 2023-2028 ($ million)
- Exhibit 96: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
- Exhibit 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity by geography
- Exhibit 99: Market opportunity by geography ($ million)
- Exhibit 100: Data Tables on Market opportunity by geography ($ million)
- 11.13 Canada - Market size and forecast (2023-2028)
- Chart on Canada - Market size and forecast (2023-2028) ($ million)
- Data Table on Canada - Market size and forecast (2023-2028) ($ million)
- Chart on Canada - Year-over-year growth (2023-2028) (%)
- Data Table on Canada - Year-over-year growth (2023-2028) (%)
- 11.14 Italy - Market size and forecast (2023-2028)
- Chart on Italy - Market size and forecast (2023-2028) ($ million)
- Data Table on Italy - Market size and forecast (2023-2028) ($ million)
- Chart on Italy - Year-over-year growth (2023-2028) (%)
- Data Table on Italy - Year-over-year growth (2023-2028) (%)
- 11.15 France - Market size and forecast (2023-2028)
- Chart on France - Market size and forecast (2023-2028) ($ million)
- Data Table on France - Market size and forecast (2023-2028) ($ million)
- Chart on France - Year-over-year growth (2023-2028) (%)
- Data Table on France - Year-over-year growth (2023-2028) (%)
- 11.16 India - Market size and forecast (2023-2028)
- Chart on India - Market size and forecast (2023-2028) ($ million)
- Data Table on India - Market size and forecast (2023-2028) ($ million)
- Chart on India - Year-over-year growth (2023-2028) (%)
- Data Table on India - Year-over-year growth (2023-2028) (%)
- 11.17 Brazil - Market size and forecast (2023-2028)
- Chart on Brazil - Market size and forecast (2023-2028) ($ million)
- Data Table on Brazil - Market size and forecast (2023-2028) ($ million)
- Chart on Brazil - Year-over-year growth (2023-2028) (%)
- Data Table on Brazil - Year-over-year growth (2023-2028) (%)
- 11.18 Egypt - Market size and forecast (2023-2028)
- Chart on Egypt - Market size and forecast (2023-2028) ($ million)
- Data Table on Egypt - Market size and forecast (2023-2028) ($ million)
- Chart on Egypt - Year-over-year growth (2023-2028) (%)
- Data Table on Egypt - Year-over-year growth (2023-2028) (%)
- 11.19 UAE - Market size and forecast (2023-2028)
- Chart on UAE - Market size and forecast (2023-2028) ($ million)
- Data Table on UAE - Market size and forecast (2023-2028) ($ million)
- Chart on UAE - Year-over-year growth (2023-2028) (%)
- Data Table on UAE - Year-over-year growth (2023-2028) (%)
- 11.20 Oman - Market size and forecast (2023-2028)
- Chart on Oman - Market size and forecast (2023-2028) ($ million)
- Data Table on Oman - Market size and forecast (2023-2028) ($ million)
- Chart on Oman - Year-over-year growth (2023-2028) (%)
- Data Table on Oman - Year-over-year growth (2023-2028) (%)
- 11.21 Argentina - Market size and forecast (2023-2028)
- Chart on Argentina - Market size and forecast (2023-2028) ($ million)
- Data Table on Argentina - Market size and forecast (2023-2028) ($ million)
- Chart on Argentina - Year-over-year growth (2023-2028) (%)
- Data Table on Argentina - Year-over-year growth (2023-2028) (%)
- 11.22 KSA - Market size and forecast (2023-2028)
- Chart on KSA - Market size and forecast (2023-2028) ($ million)
- Data Table on KSA - Market size and forecast (2023-2028) ($ million)
- Chart on KSA - Year-over-year growth (2023-2028) (%)
- Data Table on KSA - Year-over-year growth (2023-2028) (%)
10 Drivers, Challenges, and Trends
- 10.3 Impact of drivers and challenges
- Exhibit 101: Impact of drivers and challenges in 2023 and 2028
11 Vendor Landscape
- 11.2 Vendor landscape
- Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 103: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 104: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 105: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 106: Matrix on vendor position and classification
- 12.3 ATCC
- Exhibit 107: ATCC - Overview
- Exhibit 108: ATCC - Product / Service
- Exhibit 109: ATCC - Key offerings
- 12.4 Boehringer Ingelheim International GmbH
- Exhibit 110: Boehringer Ingelheim International GmbH - Overview
- Exhibit 111: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 112: Boehringer Ingelheim International GmbH - Key news
- Exhibit 113: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 114: Boehringer Ingelheim International GmbH - Segment focus
- 12.5 Corning Inc.
- Exhibit 115: Corning Inc. - Overview
- Exhibit 116: Corning Inc. - Business segments
- Exhibit 117: Corning Inc. - Key news
- Exhibit 118: Corning Inc. - Key offerings
- Exhibit 119: Corning Inc. - Segment focus
- 12.6 Danaher Corp.
- Exhibit 120: Danaher Corp. - Overview
- Exhibit 121: Danaher Corp. - Business segments
- Exhibit 122: Danaher Corp. - Key news
- Exhibit 123: Danaher Corp. - Key offerings
- Exhibit 124: Danaher Corp. - Segment focus
- 12.7 DNA TwoPointO Inc.
- Exhibit 125: DNA TwoPointO Inc. - Overview
- Exhibit 126: DNA TwoPointO Inc. - Product / Service
- Exhibit 127: DNA TwoPointO Inc. - Key offerings
- 12.8 General Electric Co.
- Exhibit 128: General Electric Co. - Overview
- Exhibit 129: General Electric Co. - Business segments
- Exhibit 130: General Electric Co. - Key offerings
- Exhibit 131: General Electric Co. - Segment focus
- 12.9 JSR Corp.
- Exhibit 132: JSR Corp. - Overview
- Exhibit 133: JSR Corp. - Business segments
- Exhibit 134: JSR Corp. - Key news
- Exhibit 135: JSR Corp. - Key offerings
- Exhibit 136: JSR Corp. - Segment focus
- 12.10 Lonza Group Ltd.
- Exhibit 137: Lonza Group Ltd. - Overview
- Exhibit 138: Lonza Group Ltd. - Business segments
- Exhibit 139: Lonza Group Ltd. - Key news
- Exhibit 140: Lonza Group Ltd. - Key offerings
- Exhibit 141: Lonza Group Ltd. - Segment focus
- 12.11 MabPlex International Ltd.
- Exhibit 142: MabPlex International Ltd. - Overview
- Exhibit 143: MabPlex International Ltd. - Product / Service
- Exhibit 144: MabPlex International Ltd. - Key offerings
- 12.12 Premas Biotech
- Exhibit 145: Premas Biotech - Overview
- Exhibit 146: Premas Biotech - Product / Service
- Exhibit 147: Premas Biotech - Key offerings
- 12.13 Promega Corp.
- Exhibit 148: Promega Corp. - Overview
- Exhibit 149: Promega Corp. - Product / Service
- Exhibit 150: Promega Corp. - Key offerings
- 12.14 Sartorius AG
- Exhibit 151: Sartorius AG - Overview
- Exhibit 152: Sartorius AG - Business segments
- Exhibit 153: Sartorius AG - Key news
- Exhibit 154: Sartorius AG - Key offerings
- Exhibit 155: Sartorius AG - Segment focus
- 12.15 Thermo Fisher Scientific Inc.
- Exhibit 156: Thermo Fisher Scientific Inc. - Overview
- Exhibit 157: Thermo Fisher Scientific Inc. - Business segments
- Exhibit 158: Thermo Fisher Scientific Inc. - Key news
- Exhibit 159: Thermo Fisher Scientific Inc. - Key offerings
- Exhibit 160: Thermo Fisher Scientific Inc. - Segment focus
- 12.16 WuXi Biologics Cayman Inc.
- Exhibit 161: WuXi Biologics Cayman Inc. - Overview
- Exhibit 162: WuXi Biologics Cayman Inc. - Product / Service
- Exhibit 163: WuXi Biologics Cayman Inc. - Key news
- Exhibit 164: WuXi Biologics Cayman Inc. - Key offerings
13 Appendix
- 13.2 Inclusions and exclusions checklist
- Exhibit 165: Inclusions checklist
- Exhibit 166: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 167: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 168: Research methodology
- Exhibit 169: Validation techniques employed for market sizing
- Exhibit 170: Information sources
- 13.5 List of abbreviations
- Exhibit 171: List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
